TickerTalks
Browse all tickers →
TickerTalks›$APLM
APAPLM

Apollomics, Inc.

$APLM·$47M·Biotechnology·Healthcare
$21.00-3.5%YTD+1.2%1Y+7.7%
Price updated 11h ago·X counts updated 4d ago
APAPLM
$APLMApollomics, Inc.
$21.00-3.54%20 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $APLM on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

20X posts · last 7 days
Sep 28Oct 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $APLM — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Apollomics regained Nasdaq compliance and raised $10M — a pre-revenue biotech with thin liquidity and April 2027 next earnings.

Apollomics is a clinical-stage oncology biopharma whose 2026 operational signals are the recently closed $10M private placement plus the regained Nasdaq compliance.

  • The P&L is pre-revenue: no quarterly revenue reported with trailing EPS prints that are very wide outlier numbers reflecting specific accounting events (Q2 2026 EPS of $3.80 is likely non-cash, with the prior Q1 2025 EPS of -$11.37 reflecting different accounting basis).
  • The specific capital-structure signals are substantive: the $10M PIPE closes anchor the balance sheet, and the Nasdaq compliance regained is a clearing event that removes listing risk — these are the kinds of signals that typically precede a specific pipeline-advancement commentary.

At 39% of its 52-week range with volume at a very thin 0.002x average, this is a thin-liquidity microcap coil on specific capital-structure clearing. A named pipeline-advancement update, additional institutional capital raise, or specific regulatory-pathway commentary is the trigger; another all-governance-process quarter without operational-pipeline signal is the invalidation.

What to watch: Next earnings in April 2027 plus any pipeline-advancement announcement — named clinical milestone, additional institutional capital raise, cash runway direction. Named milestone is the trigger; another all-process quarter is the invalidation.

On the calendar: 2027-04-01 — Full-year earnings

pre revenuecompliance cleared

Read the AI verdict on $APLM

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech developing kinase inhibitor pipeline across US and China operations targeting solid tumors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $APLM.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $APLM

Partial — Clinical-stage oncology biotech developing kinase inhibitor pipeline across US and China operations targeting solid tumors.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+35.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-15.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-111%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-20.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
288%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
100%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 27, 2026$3.80——
Q2 2025Jul 3, 2025$-11.37——
Q1 2025Apr 3, 2025$-16.92——
Q2 2024Aug 14, 2024$-37.56——
Next earningsThu, Apr 1

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$0-100.0%——$3.80$-10.4M
Q2 FY25$8.5M+1641.8%100%-125%$-11.37—
Q4 FY24$-1.6M+477.2%100%1072%$-16.92$-12.8M
Q2 FY24$1.8M+197.1%100%-1432%$-37.56$-16.0M

Forward consensus

3-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$13.3M$13.3M – $13.3M-$122.00-$122.00 – -$122.001
FY27$20.7M$20.7M – $20.7M-$138.00-$138.00 – -$138.001
FY28$12.8M$12.8M – $12.8M-$138.00-$138.00 – -$138.001

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.34%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-9.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+11.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 1.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.545-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 14Lin Peter Kuan-howCFO26.7K sh$400KBuyAug 14Yi-kuei ChenCOO20.0K sh$300KBuyAug 14Hung-wen ChenCEO536.7K sh$7.6M
+ 31 other (18 exempts · 10 awards · 3 inkinds) in window

See when $APLM insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 17SC 13D/A
AI summary

Apollomics Inc. Chairman and CEO Hung-Wen (Howard) Chen and his entity King Regent Management Limited closed a combined PIPE and note conversion on August 14, 2026. Chen acquired 370,000 shares via PIPE for approximately $5.55 million, 166,667 shares through note conversion, and 15,000 shares from RSU vesting, bringing his aggregate beneficial ownership to 1,453,029 shares (49.76% of Class A ordinary shares); King Regent holds 1,029,695 shares (35.32%). The filing is Amendment No. 2, triggered by these acquisition events. The CEO's near-majority position and significant insider accumulation signal strong insider conviction but also concentrated ownership risk.

SC 13D/AActivist amendmentAug 14SC 13D/A
AI summary

Yi-Kuei (Alex) Chen, a Taiwan-based director of Maxpro Investment Co., filed Amendment No. 1 to his Schedule 13D on Apollomics Inc. (APLM), disclosing aggregate beneficial ownership of 145,171 Class A ordinary shares representing approximately 4.97% of the class. The amendment reflects Maxpro's entry into a subscription agreement with Apollomics on August 7, 2026 to acquire additional shares; Chen holds 20,100 shares directly and shares voting/dispositive power over 125,071 shares through Maxpro (including 3,823 warrant shares). No activist intent is disclosed; this is a passive position update. The stake is just below the 5% reporting threshold, representing a minor incremental accumulation.

3New insider — initial holdingsJul 243
AI summary

Hung-Hsien Yen, a newly appointed director of Apollomics Inc. (APLM), filed an initial Form 3 on July 24, 2026 reporting beneficial ownership as of July 20, 2026. Yen holds 500 restricted stock units granted on July 20, 2026, all vesting September 15, 2026, representing contingent rights to 500 Class A Ordinary Shares; no currently owned shares are reported. The filing notes it is being made in connection with the Holding Foreign Insiders Accountable Act. This is a routine new director ownership disclosure with a de minimis equity stake.

+ 10 other (5 6-Ks · 1 D · 1 EFFECT · 1 CORRESP) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Apollomics Announces $10 Million Private Placement Transactionglobenewswire.com·66d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · last 7 days

No standout posts about $APLM on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport